Get the Stockscreener App
24.16
0.75%
0.18
After Hours:
24.67
0.51
+2.11%
Pharvaris Nv stock is traded at $24.16, with a volume of 274.37K.
It is up +0.75% in the last 24 hours and down -6.39% over the past month.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
See More
Previous Close:
$23.98
Open:
$24.1
24h Volume:
274.37K
Relative Volume:
0.83
Market Cap:
$1.57B
Revenue:
-
Net Income/Loss:
$-143.59M
P/E Ratio:
-8.5565
EPS:
-2.8236
Net Cash Flow:
$-119.47M
1W Performance:
-8.55%
1M Performance:
-6.39%
6M Performance:
+40.22%
1Y Performance:
+27.02%
1-Day Range:
$23.71
$24.62
1-Week Range:
$23.15
$26.87
52-Week Range:
$11.51
$29.80
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
24.16 | 1.56B | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Initiated | H.C. Wainwright | Buy |
| Oct-09-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-11-25 | Initiated | Guggenheim | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-25-23 | Initiated | Wedbush | Outperform |
| Aug-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-05-22 | Initiated | Bryan Garnier | Buy |
| Sep-13-22 | Resumed | JMP Securities | Mkt Outperform |
| Aug-23-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-22-22 | Downgrade | BofA Securities | Neutral → Underperform |
| May-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Mar-02-21 | Initiated | BofA Securities | Neutral |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
View All
Pharvaris Nv Stock (PHVS) Latest News
(PHVS) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary AngioedemaSlideshow (NASDAQ:PHVS) 2025-12-09 - Seeking Alpha
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? - AOL.com
Pharvaris’ Deucrictibant Provides Rapid Relief for HAE in Phase 3 RAPIDe-3 Trial - HCPLive
GENERAL ATLANTIC, L.P.'s Pharvaris NV(PHVS) Holding History - GuruFocus
Pharvaris (PHVS): Reassessing Valuation After Strong RAPIDe-3 Phase 3 Success in Hereditary Angioedema - Sahm
Pharvaris N.V. (PHVS) Price Target Increased by 20.90% to 45.73 - Nasdaq
Pharvaris (NASDAQ:PHVS) Given New $30.00 Price Target at Bank of America - MarketBeat
Why Pharvaris N.V. (9EN) stock could outperform next year2025 Retail Activity & Free Daily Entry Point Trade Alerts - Newser
Pharvaris (NASDAQ:PHVS) Price Target Raised to $30.00 at Bank of America - Defense World
B of A Securities Maintains Pharvaris N.V. (PHVS) Neutral Recommendation - Nasdaq
Guggenheim Maintains Pharvaris N.V. (PHVS) Buy Recommendation - Nasdaq
Oppenheimer Maintains Pharvaris N.V. (PHVS) Outperform Recommendation - Nasdaq
Officer Abele Files To Sell 4,109 Of Pharvaris NV [PHVS] - TradingView
Pharvaris N.V. (PHVS) Presents at BSI Clinical Immunology Professional Network (BSI-CIPN) Conference 2025Slideshow (NASDAQ:PHVS) 2025-12-04 - Seeking Alpha
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals - sharewise.com
Is Pharvaris N.V. stock undervalued vs historical averagesWeekly Market Report & Safe Capital Growth Tips - Newser
Pharvaris (NASDAQ:PHVS) Given "Buy" Rating at HC Wainwright - MarketBeat
Pharvaris (NASDAQ:PHVS) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Pharvaris' Phase 3 Trial of Deucrictibant for HAE Attacks Confirms a Differentiated On-Demand Profile, Morgan Stanley Says - marketscreener.com
Will Pharvaris N.V. stock remain a Wall Street favoriteWeekly Trade Review & Free High Accuracy Swing Entry Alerts - Newser
A new trading data show Pharvaris NV (PHVS) is showing positive returns. - setenews.com
Morgan Stanley Raises Price Target on Pharvaris to $41 From $37, Keeps Overweight Rating - MarketScreener
Pharvaris (NASDAQ:PHVS) Sets New 1-Year HighWhat's Next? - MarketBeat
Is Pharvaris N.V. (9EN) stock undervalued after correctionBull Run & Technical Pattern Based Signals - Newser
Pharvaris’ (PHVS) Buy Rating Reaffirmed at HC Wainwright - Defense World
Can Pharvaris N.V. (9EN) stock survive global slowdownQuarterly Portfolio Report & Smart Investment Allocation Insights - Newser
What momentum indicators show for Pharvaris N.V. stockJuly 2025 Reactions & Free Reliable Trade Execution Plans - Newser
CEO Modig Files To Sell 109,583 Of Pharvaris NV [PHVS] - TradingView
Pharvaris NV Stock Analysis and ForecastAnalyst Downgrades & Ask Experts in Our Investment Forum - earlytimes.in
Pharvaris (NASDAQ:PHVS) Shares Down 4.8%Time to Sell? - MarketBeat
Pharvaris’ oral deucrictibant hits endpoints in acute HAE trial - BioWorld MedTech
Pharvaris achieves primary goal in late-stage trial of deucrictibant for HAE - Seeking Alpha
Why Pharvaris Stock Is Soaring TodayPharvaris (NASDAQ:PHVS) - Benzinga
Pharvaris Shares Surge After Strong Phase 3 Results for Oral HAE Treatment - MSN
Pharvaris announces positive topline data from Rapide-3 pivotal study - marketscreener.com
Pharvaris Says Phase 3 Deucrictibant Trial Meets Endpoints in Hereditary Angioedema - marketscreener.com
Pharvaris Announces Positive Topline Data From Rapide-3 Pivotal Study - TradingView
PHVS: Deucrictibant showed rapid, significant efficacy and safety in HAE, supporting 2026 regulatory filings - TradingView
Pharvaris stock surges after positive HAE treatment study results By Investing.com - Investing.com Canada
Pharvaris stock surges after positive HAE treatment study results - Investing.com
Pharvaris Announces Positive Topline Data from RAPIDe-3 - GlobeNewswire
Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows - Sahm
Pharvaris N.V. (NASDAQ:PHVS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
How Pharvaris N.V. stock compares to growth peersJuly 2025 Fed Impact & Weekly High Return Opportunities - Newser
Is Pharvaris N.V. (9EN) stock attractive for growth fundsIPO Watch & Free Weekly Chart Analysis and Trade Guides - Newser
How (PHVS) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Pharvaris Reports Q3 2025 Financial Results and Updates - MSN
Investors in cash trouble should check out Pharvaris NV (PHVS) - Setenews
PHVS Stock Price and Chart — NASDAQ:PHVS - TradingView
Did Analyst Optimism on PHVS Pipeline Outweigh Continued Losses in Pharvaris’ Latest Results? - Sahm
Pharvaris Nv Stock (PHVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):